Details
Stereochemistry | ACHIRAL |
Molecular Formula | C30H35BrN12O5.ClH |
Molecular Weight | 760.041 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1C=C(NC(=O)C2=CC(NC(=O)C3=CC(NC(=O)C4=CC(NC(=O)C(Br)=C)=CN4C)=CN3C)=CN2C)C=C1C(=O)NCCNC(N)=N
InChI
InChIKey=IPKHXIAPPAKHTB-UHFFFAOYSA-N
InChI=1S/C30H35BrN12O5.ClH/c1-16(31)25(44)36-17-9-22(41(3)12-17)27(46)38-19-11-24(43(5)14-19)29(48)39-20-10-23(42(4)15-20)28(47)37-18-8-21(40(2)13-18)26(45)34-6-7-35-30(32)33;/h8-15H,1,6-7H2,2-5H3,(H,34,45)(H,36,44)(H,37,47)(H,38,46)(H,39,48)(H4,32,33,35);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C30H35BrN12O5 |
Molecular Weight | 723.58 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Brostallicin is a DNA minor groove binder which has shown very promising preclinical activity against a variety of human tumors both in vitro and in vivo. Brostallicin shows potent in vitro cytotoxic activity against tumor cells with IC50 values in the low nanomolar range, circumvents resistance to alkylating agents and camptothecins. Brostallicin has broad antitumor activity in animal models. A clear therapeutic gain is observed in preclinical models when brostallicin is combined with anticancer agents such as cisplatin, doxorubicin, and taxotere.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study. | 2014 Jan |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15090736
maximum tolerated doses were: 10 mg/m2 in the q3w; 2.4 mg/m2 /week in the the q1w
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:59:14 GMT 2023
by
admin
on
Fri Dec 15 17:59:14 GMT 2023
|
Record UNII |
1DKC476797
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6918407
Created by
admin on Fri Dec 15 17:59:14 GMT 2023 , Edited by admin on Fri Dec 15 17:59:14 GMT 2023
|
PRIMARY | |||
|
1DKC476797
Created by
admin on Fri Dec 15 17:59:14 GMT 2023 , Edited by admin on Fri Dec 15 17:59:14 GMT 2023
|
PRIMARY | |||
|
C128040
Created by
admin on Fri Dec 15 17:59:14 GMT 2023 , Edited by admin on Fri Dec 15 17:59:14 GMT 2023
|
PRIMARY | |||
|
DTXSID10174221
Created by
admin on Fri Dec 15 17:59:14 GMT 2023 , Edited by admin on Fri Dec 15 17:59:14 GMT 2023
|
PRIMARY | |||
|
m2728
Created by
admin on Fri Dec 15 17:59:14 GMT 2023 , Edited by admin on Fri Dec 15 17:59:14 GMT 2023
|
PRIMARY | Merck Index | ||
|
DBSALT002027
Created by
admin on Fri Dec 15 17:59:14 GMT 2023 , Edited by admin on Fri Dec 15 17:59:14 GMT 2023
|
PRIMARY | |||
|
203258-38-2
Created by
admin on Fri Dec 15 17:59:14 GMT 2023 , Edited by admin on Fri Dec 15 17:59:14 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |